Latest Articles

Publication Date
The effect of norethisterone acetate on the uterine telocytes, immune cells and progesterone receptors in albino rats.

This study is the first attempt to examine the effects of NETA on immune cells and telocytes. The results of this study form an important knowledge base for the development …

Published: March 15, 2025, midnight
FIGURE 1 MTFR2 is highly expressed in endometrial carcinoma and is a... - ResearchGate

FIGURE 1 MTFR2 is highly expressed in endometrial carcinoma and is a... ResearchGate

Published: March 14, 2025, 10:44 p.m.
Vaginal dysbiosis increases risk of endometrial polyp recurrence after hysteroscopic polypectomy: Study - Medical Dialogues

Vaginal dysbiosis increases risk of endometrial polyp recurrence after hysteroscopic polypectomy: Study Medical Dialogues

Published: March 14, 2025, 3 p.m.
Palbociclib Plus Letrozole May Increase PFS for ER+ Endometrial Cancer - www.oncnursingnews.com/

Palbociclib Plus Letrozole May Increase PFS for ER+ Endometrial Cancer www.oncnursingnews.com/

Published: March 14, 2025, 2:07 p.m.
(PDF) Comparison of diagnostic tests for chronic endometritis and endometrial dysbiosis in recurrent implantation failure: Impact on pregnancy outcomes - ResearchGate

(PDF) Comparison of diagnostic tests for chronic endometritis and endometrial dysbiosis in recurrent implantation failure: Impact on pregnancy outcomes ResearchGate

Published: March 14, 2025, 3:17 a.m.
Robotic-assisted laparoscopy increases endometrial cancer survival rates - Contemporary Obgyn

Robotic-assisted laparoscopy increases endometrial cancer survival rates Contemporary Obgyn

Published: March 13, 2025, 5:15 p.m.
Untangling Race-based Disparities in Endometrial Cancer - Medscape

Untangling Race-based Disparities in Endometrial Cancer Medscape

Published: March 13, 2025, 8:56 a.m.
Dr Wagar on the Evolution of Advanced/Recurrent Endometrial Cancer Management - OncLive

Dr Wagar on the Evolution of Advanced/Recurrent Endometrial Cancer Management OncLive

Published: March 12, 2025, 9:07 p.m.
Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer - Business Wire

Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) Launch First Phase 2 Combination Trial for Sapanisertib-Serabelisib in Patients With Endometrial Cancer Business Wire

Published: March 12, 2025, 5:34 p.m.
S2 Episode 3: Molecular Classification and Genetics of Endometrial Cancer - Medscape

S2 Episode 3: Molecular Classification and Genetics of Endometrial Cancer Medscape

Published: March 12, 2025, 4:51 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!